AZD6244 in Combination With Docetaxel Versus Docetaxel Alone in KRAS Mutation Positive NSCLC Patients
Status:
Completed
Trial end date:
2016-11-02
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the efficacy of AZD6244 in combination with docetaxel
versus docetaxel alone in patients with KRAS mutation positive locally advanced or metastatic
non small cell lung cancer.